Lavaca Capital’s iShares Biotechnology ETF IBB Stock Holding History

Lavaca Capital’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-125	Closed	-$14K	–	202
2019 Q1	$14K	Hold	125	–	–	0.01%	240
2018 Q4	$12K	Buy	+125	New	+$13.3K	0.01%	220

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Natixis Paris, France $28B AUM 26.79% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Lavaca Capital's IBB Position: Q2 2019 in Review

Lavaca Capital sold out of iShares Biotechnology ETF (IBB) in Q2 2019, closing a stake of 125 shares — an estimated $14K sold.

Lavaca Capital first reported a position in IBB in Q4 2018 and held it in 2 quarters. The position peaked at $14K in Q1 2019. 646 funds tracked by Wall St. Rank hold IBB as of Q2 2019.

Lavaca Capital reported no remaining iShares Biotechnology ETF position as of Q2 2019 after selling out during the quarter.
Lavaca Capital sold 125 iShares Biotechnology ETF shares in Q2 2019, an estimated $14K.
Lavaca Capital first reported a position in iShares Biotechnology ETF in Q4 2018 and held it in 2 quarters.
Lavaca Capital's iShares Biotechnology ETF position peaked at $14K in Q1 2019.
646 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2019.

Based on Lavaca Capital's 13F filing for Q2 2019, filed 29 Jul 2019.